Revvity and Lilly partner to accelerate AI drug discovery models
Collaboration funds participating biotechs to access Lilly predictive models through the Revvity Signals Xynthetica offering
Collaboration funds participating biotechs to access Lilly predictive models through the Revvity Signals Xynthetica offering
The new facility offers an expanded laboratory alongside meeting areas dedicated to development meetings, formulation workshops, and brainstorming sessions
The supplements are made using only vegetarian-sourced ingredients
This is the first controlled pharmacologic study to demonstrate that treatment of obesity improved PsA disease measures
Phase 3 study met all primary and secondary endpoints, demonstrating superior convenience, strong efficacy, and excellent safety versus conventional ondansetron injections
This product has only one approved generic and one authorized generic with an addressable market share of US$ 172 million
The partnership builds on a prior collaboration between Nimbus and Lilly targeting AMPK in cardiometabolic diseases
The Phase 1 study, a non-randomised, open-label, multicentre trial, is evaluating IKS014 in patients with locally advanced or metastatic solid tumours expressing HER2
The FDA designation follows visual-function results from the Phase 2 ACUITY trial
Subscribe To Our Newsletter & Stay Updated